Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
ConditionLymphoma, Non-Hodgkin
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorThe First People's Hospital of Changzhou
About this trial
The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
Eligibility criteria
Qualifiers
diagnosed as non-Hodgkin lymphoma with negative effect of regular chemotherapy, and need further therapy
Disqualifiers
patients refuse the therapy or have no tolerance for the therapy
Trial design
Treatments tested in this trial
- Cytokine-induced killer cells (CIK)
Treatment groups
1,000 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov